The recent FDA approvals of brentuximab vedotin (Adcetris®; Seattle Genetics) andtrastuzumab emtansine (Kadcyla®; Genentech/Roche), show that antibody-drug conjugates are indeed becoming an important class of biotherapeutics in oncology.

The strong pipeline of ADC in clinical development, bearing 38 ADC for the treatment of both solid and hematological malignancies, further emphasizes the interest and confidence of both clinicians and pharmaceutical industry in the area.

Although the ADC concept looks pretty simple, it took decades before ADCs turned out to be a successful therapeutic option. Improving the understanding of the mechanism of action of antibody-drug conjugates allowed researchers to identify the most critical factors influencing the efficacy and toxicity of these new drugs.

MabPlex
Broadpharm
Lonza
ADC Bio
 

This better understanding has led to still ongoing research efforts in antibody and alternative scaffold engineering, in linker and conjugation chemistry, as well as in the screening and selection of optimal target antigens and cytotoxics.

In a review article, published in Médecine/Sciences (M/S Revues), Emmanuelle Vigne (Sanofi, Global Biotherapeutics) and Ingrid Sassoon (Sanofi Oncology), discuss the current state of development and future of antibody-drug conjugates.

Published in: Médecine/Sciences (M/S Revues)

Previous articleBroad Patent For Antibody Development
Next articleBicycle Therapeutics Secures Equity Financing for Clinical Development Program
ADC Review
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) launched in 2013, is designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, (basic, translational and clinical) research, clinicians/physicians, along with regulatory affairs, government authorities and representatives from payers, and policy makers. The Journal’s content includes peer reviewed research, commentaries, news features, discussions, editorials and blogs on topics relevant to a broad international readership. The Journal also offers a knowledge center (called ADC University) offering the latest and most relevant information about Antibody-drug Conjugates (ADCs), BiSpecific Antibodies, Site Specific Antibody Drug Conjugates, Small Molecule Drug Conjugates (SMDC), and Engineered Antibody Fragments. The purpose of the Journal is to present this information in an understandable and a useful format for all stakeholders.